Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00588536 · ClinicalTrials.gov registry record · Phase 2
Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH
A Phase 2 study of Langerhans Cell Histiocytosis, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT00588536: Completed Phase 2 study of Langerhans Cell Histiocytosis, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00588536 is a Phase 2 study of Langerhans Cell Histiocytosis that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 5 participants, below the 1,138-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00588536, a Phase 2 study of Langerhans Cell Histiocytosis, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to determine the incidence of complete and partial response and the duration of response in patients with Langerhans Cell Histiocytosis (LCH) treated with sequential administration of oral 6-Thioguanine (6-TG) after Methotrexate (MTX).
Conditions Studied
Interventions
- DRUG Leucovorin Calcium
- DRUG Methotrexate
- DRUG 6-Thioguanine
Study Locations (1)
New York
- Memorial Sloan-Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 1995-01 |
| Est. Completion | 2009-06 |
| Phase | Phase 2 |
What the finished NCT00588536 record still lists
NCT00588536 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 1,138-participant average among 8 other Langerhans Cell Histiocytosis trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Langerhans Cell Histiocytosis appearing as the primary indexed condition, and to 3 interventions - of which Leucovorin Calcium is the first listed.
NCT00588536 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00588536 about?
NCT00588536 is a clinical study titled "Study of Sequential Administration of Oral 6-Thioguanine After Methotrexate in Patients With LCH". The objective of this study is to determine the incidence of complete and partial response and the duration of response in patients with Langerhans Cell Histiocytosis (LCH) treated with sequential administration of oral 6-Thioguanine (6-TG) after Methotrexate (MTX).
What is the current status of trial NCT00588536?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 1995-01. Estimated completion is 2009-06.
What conditions does trial NCT00588536 study?
This clinical trial studies the following conditions: Langerhans Cell Histiocytosis.
What interventions are being tested in trial NCT00588536?
The interventions under investigation include: Leucovorin Calcium (DRUG), Methotrexate (DRUG), 6-Thioguanine (DRUG).
Who is sponsoring clinical trial NCT00588536?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00588536 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Langerhans Cell Histiocytosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00588536's enrollment target sits among peer trials
5 9th of 8 the lowest of 8 other Langerhans Cell Histiocytosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Langerhans Cell Histiocytosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
RECRUITING · Phase 2
-
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
RECRUITING · Phase 2
-
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
RECRUITING · Phase 2
-
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Study of Clofarabine in Patients With Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Test the Ability of and Safety of GSK2110183 in Treating Langerhans Cell Histiocytosis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia